{"filing":{"accession_number":"0001493152-26-035546","cik":"0001847846","ticker":"EUDAW","company_name":"EUDA Health Holdings Ltd","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1847846/000149315226035546/form6-k.htm"},"events":[{"id":22317,"run_id":20176,"accession_number":"0001493152-26-035546","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"EUDA Health announced a non-binding Memorandum of Understanding (MOU) signed July 15, 2026, with GO POSB and SIIT to collaborate on developing and commercializing integrated iPSC cell therapy products for oncology and wellness applications. The announcement details EUDA's role in funding, facilitating commercialization, and supporting global market access for next-generation cell therapies. This is a material strategic partnership and operational initiative that would affect a reasonable investor's assessment of the company's growth strategy and future product pipeline, though the MOU is non-binding and subject to definitive agreements and regulatory approvals.","company_name":"EUDA Health Holdings Ltd","ticker":"EUDAW","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":[{"id":22226,"accession_number":"0001493152-26-035546","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"EUDA Health announced a non-binding Memorandum of Understanding (MOU) signed July 15, 2026, with GO POSB and SIIT to collaborate on developing and commercializing integrated iPSC cell therapy products for oncology and wellness applications. The announcement details EUDA's role in funding, facilitating commercialization, and supporting global market access for next-generation cell therapies. This is a material strategic partnership and operational initiative that would affect a reasonable investor's assessment of the company's growth strategy and future product pipeline, though the MOU is non-binding and subject to definitive agreements and regulatory approvals.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:00:44.813506+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22226,"accession_number":"0001493152-26-035546","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"EUDA Health announced a non-binding Memorandum of Understanding (MOU) signed July 15, 2026, with GO POSB and SIIT to collaborate on developing and commercializing integrated iPSC cell therapy products for oncology and wellness applications. The announcement details EUDA's role in funding, facilitating commercialization, and supporting global market access for next-generation cell therapies. This is a material strategic partnership and operational initiative that would affect a reasonable investor's assessment of the company's growth strategy and future product pipeline, though the MOU is non-binding and subject to definitive agreements and regulatory approvals.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:00:44.813506+00:00","company_name":"EUDA Health Holdings Ltd","ticker":"EUDAW","filing_date":"2026-07-31"}]}